Schindler C, Fooks A, Stephenson J, Liebert U G
Institut für Virologie und Immunobiologie, Universität Würzburg, Germany.
Behring Inst Mitt. 1994 Dec(95):109-15.
Despite the availability of an efficient live-attenuated measles virus vaccine about 1.5 million annual deaths from measles infections and their complications are recorded worldwide. Particularly in developing countries measles remains an unsolved problem and a new vaccine seems necessary. In our animal model of measles virus infection in rats we studied a candidate vaccine based on infectious replication incompetent (E1A-) adenovirus (RAd) where measles virus genes are expressed under the control of the cytomegalovirus immediate early promoter. The aim of the study was to characterize the cell mediated and humoral immunity after immunization with RAd and its protective effect. After challenge with a lethal dose of measles virus no signs of disease or histopathological changes were detected in RAd68-immunized rats. The elimination of measles virus was successful within a few days. The results demonstrate that defective recombinant adenovirus vectors can induce complete protection from experimental measles infection in rats.
尽管有高效的减毒活麻疹病毒疫苗,但全球每年仍有150万人死于麻疹感染及其并发症。特别是在发展中国家,麻疹仍然是一个未解决的问题,似乎需要一种新的疫苗。在我们的大鼠麻疹病毒感染动物模型中,我们研究了一种基于感染性复制缺陷型(E1A-)腺病毒(RAd)的候选疫苗,其中麻疹病毒基因在巨细胞病毒立即早期启动子的控制下表达。该研究的目的是表征用RAd免疫后的细胞介导免疫和体液免疫及其保护作用。在用致死剂量的麻疹病毒攻击后,在RAd68免疫的大鼠中未检测到疾病迹象或组织病理学变化。麻疹病毒在几天内被成功清除。结果表明,缺陷型重组腺病毒载体可以诱导大鼠对实验性麻疹感染产生完全保护。